Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pevonedistat - Takeda Oncology

Next Previous
X
Search
Drug Profile

Pevonedistat - Takeda Oncology

Alternative Names: MLN-4924; MLN4924-003; Pevonedistat hydrochloride; TAK 924

Latest Information Update: 05 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Case Western Reserve University; Children's Oncology Group; Eli Lilly and Company; Greehey Childrens Cancer Research Institute; Louisiana State University; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Nationwide Children's Hospital; PETHEMA Foundation; Takeda Oncology; Translational Genomics Research Institute; University of Miami; University of Michigan Comprehensive Cancer Center; University of Southampton; University of Southern California; University of Texas M. D. Anderson Cancer Center; Vanderbilt-Ingram Cancer Center; Washington University School of Medicine
  • Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Antirheumatics; Cyclopentanes; Indenes; Pyrimidines; Pyrroles; Small molecules; Sulfonic acids
  • Mechanism of Action NEDD 8 activating enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Rheumatoid arthritis
  • Discontinued Acute myeloid leukaemia; Cholangiocarcinoma; Chronic myelomonocytic leukaemia; Glioblastoma; Lymphoma; Mesothelioma; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders; Non-small cell lung cancer; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Renal cell carcinoma; Rhabdomyosarcoma; Solid tumours

Most Recent Events

  • 14 Oct 2024 Takeda completes the phase III PANTHER trial in Acute myeloid leukaemia, Chronic myelomonocytic leukaemia and Myelodysplastic syndromes (Combination therapy, First-line therapy, In adults, In the elderly) in the US, Spain, Australia, Belgium, Brazil, Canada, China, Czech Republic, France, Germany, Greece, Israel, Italy, Japan, South Korea, Mexico, Poland, Russia, Turkey, United Kingdom (IV), (NCT03268954),
  • 13 Jun 2024 Efficacy and adverse events data from a phase III trial in Acute myeloid leukemia presented at the 29th Congress of the European Haematology Association (EHA-2024)
  • 05 Apr 2024 Pharmacodynamics data from a phase II trial in Acute myeloid leukemia presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top